Clovis Oncology’s (CLVS) “Outperform” Rating Reiterated at Credit Suisse Group AG
Clovis Oncology Inc. (NASDAQ:CLVS)‘s stock had its “outperform” rating restated by investment analysts at Credit Suisse Group AG in a report issued on Monday. They presently have a $41.00 price objective on the biopharmaceutical company’s stock. Credit Suisse Group AG’s target price would suggest a potential upside of 27.57% from the company’s current price.
A number of other research firms have also issued reports on CLVS. SunTrust Banks Inc. upped their target price on shares of Clovis Oncology from $38.00 to $50.00 and gave the company a “buy” rating in a report on Friday, September 23rd. Zacks Investment Research lowered shares of Clovis Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, October 4th. Janney Montgomery Scott lowered shares of Clovis Oncology from a “buy” rating to a “neutral” rating and upped their target price for the company from $35.00 to $36.00 in a report on Wednesday, September 21st. Stifel Nicolaus upped their target price on shares of Clovis Oncology from $30.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, September 21st. Finally, Mizuho upped their target price on shares of Clovis Oncology from $15.00 to $23.00 and gave the company a “neutral” rating in a report on Wednesday, August 24th. Seven equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $34.06.
Shares of Clovis Oncology (NASDAQ:CLVS) traded up 9.38% on Monday, hitting $32.17. 4,552,507 shares of the company were exchanged. Clovis Oncology has a 52-week low of $11.57 and a 52-week high of $109.18. The company has a 50-day moving average price of $29.42 and a 200 day moving average price of $18.69. The firm’s market cap is $1.24 billion.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/clovis-oncologys-clvs-outperform-rating-reiterated-at-credit-suisse-group-ag.html
Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($2.07) EPS for the quarter, topping the consensus estimate of ($2.13) by $0.06. During the same quarter in the previous year, the business earned ($2.10) earnings per share. Analysts predict that Clovis Oncology will post ($9.25) EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of the company. Parametric Portfolio Associates LLC acquired a new stake in Clovis Oncology during the second quarter worth about $144,000. Fox Run Management L.L.C. acquired a new stake in Clovis Oncology during the second quarter worth about $154,000. CIBC World Markets Inc. increased its stake in Clovis Oncology by 7.8% in the first quarter. CIBC World Markets Inc. now owns 11,680 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 850 shares during the period. Schonfeld Strategic Advisors LLC acquired a new stake in Clovis Oncology during the first quarter worth about $233,000. Finally, Royal Bank of Canada increased its stake in Clovis Oncology by 2,075.9% in the second quarter. Royal Bank of Canada now owns 18,212 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 17,375 shares during the period. 98.46% of the stock is owned by hedge funds and other institutional investors.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.